Señales en vivo de NVAX | Maximiza tus Ganancias con Getagraph.com

VENDER 66427 min ago

@ $5.28

Emitido: 13 mar 2024 @ 14:02

Retorno: -22.55%

Señal anterior: mar 13 - 13:12

Señal anterior: Comprar

Retorno: 1.36 %

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 16:00):

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs...

Stats
Volumen de hoy	3.01M
Volumen promedio	7.13M
Capitalización de mercado	572.41M
EPS	$0 ( 2024-02-28 )
Próxima fecha de ganancias	( $-1.040 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.760
ATR14	$0.00800 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Trizzino John	Buy	144 000	Restricted Stock Units
2024-03-01	O'hara Elaine	Buy	120 000	Restricted Stock Units
2024-03-01	Kelly James Patrick	Buy	176 000	Restricted Stock Units
2024-03-01	Dubovsky Filip	Buy	144 000	Restricted Stock Units
2024-03-01	Casey Mark J	Buy	12 000	Restricted Stock Units

INSIDER POWER
62.98
Last 99 transactions
Buy: 1 952 927 \| Sell: 481 828

Volumen Correlación

Largo: -0.13 (neutral)

Corto: -0.71 (moderate negative)

Signal:(49.895) Neutral

Novavax Inc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novavax Inc Correlación - Moneda/Commodity

-0.29
( neutral )

-0.27
( neutral )

0.00
( neutral )

-0.32
( neutral )

Novavax Inc Finanzas

Annual	2023
Ingresos:	$983.71M
Beneficio Bruto:	$704.24M (71.59 %)
EPS:	$-5.41

FY	2023
Ingresos:	$983.71M
Beneficio Bruto:	$704.24M (71.59 %)
EPS:	$-5.41

FY	2022
Ingresos:	$1.60B
Beneficio Bruto:	$696.31M (43.55 %)
EPS:	$-8.42

FY	2021
Ingresos:	$1.15B
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-23.44

Financial Reports:

No articles found.

Novavax Inc

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.